NCT07246863 2026-03-04
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
Phase 2 Recruiting
Clinical Trials
14 trialsNCT07219459 2025-10-21
GDFATHERHCC01
CatalYm GmbH
Phase 2 Not yet recruiting
NCT05951777 2025-09-29
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Hope Biosciences Research Foundation
Phase 2 Recruiting
NCT05163223 2024-06-17
Cornerstone001
Aston Sci. Inc.
Phase 2 Terminated
NCT05493800 2024-05-29
Capella
MitoImmune Therapeutics
Phase 2 Active not recruiting
NCT02663622 2024-01-23
MK-7110-002
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Completed
NCT05794659 2023-07-20
Cornerstone4
Aston Sci. Inc.
Phase 2 Not yet recruiting
NCT01403064 2021-05-11
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
CSL Behring
Phase 2 Terminated
NCT01687387 2019-02-08
EFFIKIR
Innate Pharma
Phase 2 Completed
NCT00614393 2018-08-08
Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00738699 2017-03-30
FAR-122
Morphotek
Phase 2 Terminated
NCT00850577 2015-10-12
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 2 Terminated
NCT00851045 2015-10-12
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00669747 2008-10-02
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
Windy Hill Medical, Inc.
Phase 2 Unknown